HC Wainwright Has Lowered Expectations for Jasper Therapeutics (NASDAQ:JSPR) Stock Price

Jasper Therapeutics (NASDAQ:JSPR) had its price objective lowered by equities researchers at HC Wainwright from $60.00 to $40.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 472.25% from the company’s previous close. HC Wainwright also issued estimates for Jasper Therapeutics’ FY2029 earnings at ($10.81) EPS.

Several other analysts have also recently issued reports on JSPR. JMP Securities reiterated a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a research report on Monday. BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective on the stock. Finally, Royal Bank of Canada dropped their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $67.75.

Jasper Therapeutics Price Performance

Shares of NASDAQ JSPR opened at $6.99 on Friday. The stock has a market cap of $104.86 million, a PE ratio of -1.47 and a beta of 2.18. Jasper Therapeutics has a 1 year low of $6.61 and a 1 year high of $31.01. The firm has a fifty day moving average price of $21.66 and a 200-day moving average price of $20.37.

Institutional Investors Weigh In On Jasper Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Samsara BioCapital LLC lifted its holdings in shares of Jasper Therapeutics by 11.4% in the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after acquiring an additional 59,642 shares during the last quarter. Braidwell LP bought a new stake in Jasper Therapeutics in the third quarter worth about $9,091,000. Ally Bridge Group NY LLC boosted its position in shares of Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after buying an additional 180,852 shares during the period. State Street Corp grew its stake in shares of Jasper Therapeutics by 12.3% during the third quarter. State Street Corp now owns 214,883 shares of the company’s stock valued at $4,042,000 after buying an additional 23,564 shares during the last quarter. Finally, Fernwood Investment Management LLC raised its holdings in shares of Jasper Therapeutics by 6.9% in the third quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock worth $995,000 after buying an additional 3,427 shares during the period. 79.85% of the stock is owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.